Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Procedures for ablation of persistent or long lasting atrial fibrillation are frequently long
and require extensive ablation. Some electrophysiologists administer the drug ibutilide
during these procedures to help organize the fibrillatory activity of the left atrium with
the hope that this may shorten the length of the procedure and duration of ablation needed.
Currently there is no standardized approach of administering the drug ibutilide during these
procedures, thus the investigators cannot be certain that administering this drug does in
fact facilitate the procedure. The aim of the MAGIC-AF Trial is to see if administering a
standard dose of the drug ibutilide at a standard time in the procedure can allow for a
reduction in the ablation procedure time. The investigators hypothesize that administering
ibutilide during these procedures will result in a reduction in the procedure and ablation
time required.